66395-18-4

Upstream product

• 26922-56-5 N-Methyl-N'-(β-D-mannopyranosyl)-harnstoff 
• 55324-99-7 N-Nitroso-methylcarbamidazid 
• 1772-03-8 D-(+)-galactosamine hydrochloride 
• 90-76-6 D-galactosamine 
• 26922-56-5 1-methyl-3-(2-deoxy-D-galactos-2-yl)urea 
• 624-83-9 methyl isocyanate 
• 90-76-6 D-mannosamine 
• 26922-56-5 1-methyl-3-(2-deoxy-D-mannos-2-yl)urea 
• 4710-95-6 D-mannosamine hydrochloride 
• 6490-72-8 β-mannosamine 

Downstream Products

• 186581-53-3 diazomethane 
• 67-56-1 methanol 
• 74-89-5 methylamine 
• 136598-81-7 1-methyl-1-nitroso-3-(1,3,4,6-tetra-O-acetyl-2-deoxy-D-mannos-2-yl)urea 
• 136598-80-6 1-methyl-1-nitroso-3-(1,3,4,6-tetra-O-acetyl-2-deoxy-D-galactos-2-yl)urea 
• 1613414-91-7 (R)-3-((S)-(3-((5-((4-((R)-2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethylamino)butoxy)carbonyl)furan-2-yl)methoxy)phenyl)-(phenyl)methylcarbamoyloxy)-1-(2-oxo-2-(thiophen-2-yl)ethyl)-1-azoniabicyclo[2.2.2]octane chloride hydrochloride 

Relevant academic research and scientific papers

THERAPEUTIC FOR HEPATIC CANCER

A novel pharmaceutical composition for treating or preventing hepatocellular carcinoma and a method of treatment are provided. A pharmaceutical composition for treating or preventing liver cancer is obtained by combining a chemotherapeutic agent with an anti-glypican 3 antibody. Also disclosed is a pharmaceutical composition for treating or preventing liver cancer which comprises as an active ingredient an anti-glypican 3 antibody for use in combination with a chemotherapeutic agent, or which comprises as an active ingredient a chemotherapeutic agent for use in combination with an anti-glypican 3 antibody. Using the chemotherapeutic agent and the anti-glypican 3 antibody in combination yields better therapeutic effects than using the chemotherapeutic agent alone, and mitigates side effects that arise from liver cancer treatment with the chemotherapeutic agent.

In the search for new anticancer drugs. XXIII: Exploration of a predictive design for anticancer drugs of carbohydrates containing N-nitrosochloroethylamino, N-nitrosomethyl, and N-nitrosoaminoxyl components

The spin-labeled glucose nitrosoureas 13-16, streptozotocin (18), chlorozotocin (31), streptozotocin analogues of galactosyl 24 and mannosyl 28, and their tetra-O-acetyl derivatives 25 and 29, MCNU (Cymerin, 34), and glucamine (21) were synthesized and evaluated in vivo for their anticancer activities against the murine lymphocytic leukemia P388. Compounds 13-16, 18, 24, 28, 31, and 34 possessed activities ranging from 33 to 603% increase in life span (%ILS), whereas 21, 25, and 29 were inactive (%ILS = 9 to 10). All CD2F1 male mice treated with the most active compounds (13, 14, and 34) at 20 mg/kg were alive after 30 days, whereas all mice treated with the clinical drug streptozotocin (18) and clinically tested chlorozotocin (31) succumbed. Compounds 13-16, 18, 31, and 34 were further evaluated for their antineoplastic activity against lymphoid leukemia L1210. Compounds 13 and 34 on day 60 exhibited %ILS values of 557 and 713, respectively, as compared with %ILS values of 646 and 713 for CCNU (1) and the spin-labeled SLCNU (3), respectively. The lipophilicities of 13-16, 18, 21, 24, 25, 28, 29, 31, and 34 were determined using EPR and/or UV methods. A predictive design pattern was observed, with the most active drug (34) possessing some hydrophobic property (log P = 1.24), followed by 13 (log P = 1.87) and 14 (log P = 1.81) as the more active drugs with higher hydrophobicity than 34. The clinical drugs streptozotocin (18) and chlorozotocin (31) were distinctly hydrophilic and less active. Finally, it was concluded that various scattered results of anticancer activity in the literature can be explained by a linear correlation of activities with lipophilicities.

Method of treating nausea and vomiting with certain substituted-phenylalkylamino (and aminoacid) derivatives and other serotonin depleting agents

A method for the treatment of emesis in a mammal, which method comprises administering to said mammal an emesis inhibiting amount of a compound which depletes serotonin in the brain of mammals; among which are compounds having the formula: STR1 wherein, R is selected from hydrogen, loweralkyl, trifluoromethyl, carboxyl, or loweralkoxycarbonyl; R1 and R2 are hydrogen or loweralkyl; Z is trifluoromethyl or halogen; the optical isomers and pharmaceutically acceptable salts thereof; two of the preferred compounds of the invention are fenfluramine and norfenfluramine.

Process for producing glucopyranose-nitrosourea compounds and novel compounds included therein

Glucopyranose-nitrosourea compounds having lower alkyl group and/or 2-chloroethyl group as substituent(s), are produced at high yield by reacting amino-glucopyranose compounds having lower alkoxy group and/or amino group(s) (or an acid-added amino group) as substituent(s), with o-nitro- or o-cyano-phenyl N-substituted-N-nitrosocarbamate compounds having lower alkyl group or 2-chloroethyl group as substituent. 1-(Lower alkyl or 2-chloroethyl)-3-(D-glucopyranos-6-yl)-1-nitrosourea compounds included within the scope of the nitrosourea compounds are novel. The nitrosourea compounds produced by this invention all show antitumor activity, among which the novel compounds exhibit excellent physical and pharmacological properties.